歐洲、亞太、拉丁美洲以及中東和非洲的尿道感染（UTI）疫苗市場：按疫苗類型、目標病原體、年齡層、給藥途徑和銷售管道

Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type, By Pathogen Targeted, By Age Group, By Route of Administration, By Sales Channel

出版日期: 2026年08月27日 | 出版商:

Coherent Market Insights | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，歐洲、亞太地區、拉丁美洲以及中東和非洲的尿道感染（UTI）疫苗市場規模將達到6,278.59億美元，到2033年將達到1.15476億美元。預計從2026年到2033年，該市場將以11.2%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	62,785,900 美元
歷史數據涵蓋的時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.20%	2033年市場規模預測：	115,476,000 美元

預計在預測期內，歐洲、亞太、拉丁美洲以及中東和非洲的尿道感染（UTI）疫苗市場將呈現顯著成長，其主要促進因素包括復發性尿路感染負擔的加重、抗菌素抗藥性的日益嚴重以及對替代抗生素療法的需求不斷成長。疫苗研發主要集中於大腸桿菌等病原體，全細胞疫苗、次單位疫苗和結合疫苗等方法在臨床和研究領域中日益受到重視。

區域市場機會受醫療基礎設施、疾病流行程度、法規環境以及預防性療法的可近性等因素所驅動。歐洲和亞太地區由於醫療體係成熟且臨床研發活動日益活躍，預計仍將是關鍵市場。同時，拉丁美洲和中東及非洲作為新興市場，醫療服務覆蓋範圍不斷擴大，新型預防性療法的應用也日益普及。

市場動態

歐洲、亞太、拉丁美洲以及中東和非洲的尿道感染（UTI）疫苗市場主要受復發性泌尿道感染發病率上升和抗生素抗藥性日益嚴重的推動。這凸顯了除反覆使用抗生素治療外，預防性措施的迫切需求。疫苗研發的進步、對細菌疫苗候選藥物投資的增加以及臨床上對大腸桿菌和其他尿路病原體日益成長的關注，都在推動著關鍵地區的市場發展。

然而，該市場面臨許多限制因素，包括已通過核准的泌尿道感染疫苗數量有限、臨床研發週期長，以及對多種細菌菌株的有效性尚不明確。儘管如此，針對復發性和抗藥性泌尿道感染的疫苗仍蘊藏著巨大的市場機遇，尤其是在高風險成人和老年族群。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，介紹了歐洲、亞太地區、拉丁美洲以及中東和非洲尿道感染(UTI) 疫苗市場的主要公司概況：公司概況、產品系列、主要亮點、財務績效和策略。
透過利用本報告中的見解，各公司的行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
歐洲、亞太、拉丁美洲以及中東和非洲的尿道感染疫苗市場報告針對行業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用各種策略矩陣來簡化決策過程，這些矩陣用於分析歐洲、亞太地區、拉丁美洲以及中東和非洲的尿道感染(UTI) 疫苗市場。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 62,785.9 Thousands
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.20%	2033 Value Projection:	USD 115,476.0 Thousands

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is expected to grow at a significant rate during the forecast period owing to the increasing burden of recurrent UTIs, growing antimicrobial resistance and the need for alternatives to repeated antibiotic use. The vaccine development is primarily focused on pathogens such as Escherichia coli, with whole-cell, subunit and conjugate approaches gaining interest in the clinical and research pipelines.

The regional market opportunities are dependent on healthcare infrastructure, disease prevalence, regulatory environments and the availability of preventive therapies. Europe and Asia Pacific will continue to be key markets due to mature healthcare systems and increasing clinical development activities whereas Latin America and the Middle East & Africa are emerging markets with growing healthcare access and uptake of novel preventive therapies.

Market Dynamics

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is primarily driven by rising incidence of recurrent UTIs and growing antimicrobial resistance, which is increasing the need for preventive approaches beyond repeated antibiotic treatment. Advances in vaccine research, growing investment in bacterial vaccine candidates, and increasing clinical focus on Escherichia coli and other uropathogens are supporting market development across key regions.

However, a number of constraints are present in the market, such as limited availability of approved UTI vaccines, long clinical development timeframes and uncertain efficacy across a wide range of bacterial strains. Nevertheless, significant opportunities exist in vaccines targeting recurrent and drug-resistant UTIs, particularly among high-risk adult and elderly populations.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include INMUNOTEK S.L., OM Pharma SA, Sequoia Vaccines, Inc., GlaxoSmithKline Biologicals SA, Strathmann GmbH & Co. KG, Legacy Pharmaceuticals Switzerland GmbH, CureVac SE, Janssen-Cilag International NV, Sanofi, and GlycoVaxyn AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market

Market Segmentation

Vaccine Type Insights (Revenue, USD Th, 2021 - 2033)
Bacterial whole-cell Vaccines
Subunit Vaccines
Conjugate Vaccines
Live-Attenuated Vaccines
Others
Pathogen Targeted Insights (Revenue, USD Th, 2021 - 2033)
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Other Targeted Pathogens
Age Group Insights (Revenue, USD Th, 2021 - 2033)
Pediatric
Adults
Elderly
Route of Administration Insights (Revenue, USD Th, 2021 - 2033)
Parenteral
Oral
Sublingual
Intranasal
Sales Channel Insights (Revenue, USD Th, 2021 - 2033)
Hospitals and Clinic Pharmacies
Retail pharmacies
Others
Key Players Insights
INMUNOTEK S.L.
OM Pharma SA
Sequoia Vaccines, Inc.
GlaxoSmithKline Biologicals SA
Strathmann GmbH & Co. KG
Legacy Pharmaceuticals Switzerland GmbH
CureVac SE
Janssen-Cilag International NV
Sanofi
GlycoVaxyn AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration
- Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Bacterial whole-cell Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Subunit Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Conjugate Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Live-Attenuated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

5. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Escherichia coli
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Klebsiella pneumoniae
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Pseudomonas aeruginosa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Other Targeted Pathogens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

6. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Elderly
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

7. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Sublingual
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

8. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel, 2021-2033, (USD Th)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals and Clinic Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

9. Competitive Landscape

Company Profile
- INMUNOTEK S.L.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- OM Pharma SA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sequoia Vaccines, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GlaxoSmithKline Biologicals SA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Strathmann GmbH & Co. KG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Legacy Pharmaceuticals Switzerland GmbH
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- CureVac SE
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Janssen-Cilag International NV
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GlycoVaxyn AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies